| abstract |
Use of interferon-alfa, e.g., pegylated interferon alfa-2a or 2b for preparation of a medicament for promotion of an HIV-1 specific immune response, e.g., promotion of HIV-1 specific T-cells, in adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV comprising a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b is disclosed. |